| Recruiting | A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine NCT07018700 | Merz Therapeutics GmbH | Phase 3 |
| Recruiting | Efficacy of Gou-Teng-San (GTS) in Patients With Episodic Migraine: A Double-Blind Randomized Controlled Trial NCT07496034 | Tsai, Chueh-Yi, MD | Phase 3 |
| Recruiting | Chiropractic Care for Episodic Migraine NCT06229834 | Brigham and Women's Hospital | N/A |
| Recruiting | Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine NCT06882122 | IRCCS National Neurological Institute "C. Mondino" Foundation | — |
| Recruiting | A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults NCT06625060 | Ipsen | Phase 2 |
| Recruiting | Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for NCT06603558 | AbbVie | — |
| Completed | Greater Occipital Nerve Blockade and Sphenopalatine Ganglion Blockade in Patients With Episodic Migraine NCT06997562 | New Valley University | N/A |
| Recruiting | Prophylactic Treatment With Atorvastatin for Episodic Migraine. NCT06248671 | St. Olavs Hospital | Phase 2 |
| Recruiting | Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine NCT07159750 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Completed | Mi-Helper Transnasal Cooling for Acute Treatment of Migraine NCT06051604 | CoolTech LLC | N/A |
| Active Not Recruiting | A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults NCT06047457 | Ipsen | Phase 3 |
| Completed | Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C) NCT06004388 | Click Therapeutics, Inc. | Phase 3 |
| Recruiting | Efficacy of Nerve Blocks for Episodic Migraine NCT05734625 | Mayo Clinic | Phase 2 |
| Recruiting | A Study of Eptinezumab in Pediatric Participants With Episodic Migraine NCT05897320 | H. Lundbeck A/S | Phase 3 |
| Recruiting | Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments NCT06562400 | IRCCS National Neurological Institute "C. Mondino" Foundation | — |
| Recruiting | Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments NCT06562413 | IRCCS National Neurological Institute "C. Mondino" Foundation | — |
| Recruiting | Biochemical Profiling of Migraine Patients NCT06549270 | IRCCS National Neurological Institute "C. Mondino" Foundation | — |
| Recruiting | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Par NCT05711394 | AbbVie | Phase 3 |
| Completed | Study of Two Digital Therapeutics for the Prevention of Episodic Migraine NCT05853900 | Click Therapeutics, Inc. | N/A |
| Unknown | The Effect of Daylight Saving Time Transitions on Sleep and Migraine Headaches. NCT05742191 | OSF Healthcare System | — |
| Recruiting | Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification NCT06674772 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Unknown | Probiotics as Adjunctive Migraine Prophylaxis NCT05042037 | Universiti Putra Malaysia | N/A |
| Unknown | Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study NCT05281770 | Austrian Migraine Registry Collaboration | — |
| Completed | Cerebri Biofeedback Feasibility Trial NCT05454319 | Nordic Brain Tech AS | N/A |
| Unknown | The Effects of Vitamin D Plus Omega-3 Polyunsaturated Fatty Acids in Patients With Episodic Migraine NCT05449145 | Kuang Tien General Hospital | N/A |
| Unknown | Sphenopalatine Ganglion Blockade in Migraine NCT05210192 | Afyonkarahisar Health Sciences University | Phase 3 |
| Recruiting | i-NEED: NEw migrainE Drugs Database NCT07103694 | IRCCS San Raffaele Roma | — |
| Completed | Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention NCT05207865 | Pfizer | Phase 4 |
| Completed | Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat NCT05264129 | AbbVie | Phase 4 |
| Unknown | Effectiveness of Multimodal Physical Therapy in Migraine NCT05226559 | Neuromed IRCCS | N/A |
| Completed | A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine NCT05127486 | Eli Lilly and Company | Phase 4 |
| Terminated | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine NCT05028569 | AbbVie | Phase 3 |
| Terminated | Transnasal Cooling for Migraine NCT04936061 | CoolTech LLC | N/A |
| Unknown | My Healthy Diary - An Electronic Diary for Remote Migraine Monitoring NCT04828941 | Unidade Local de Saúde de Matosinhos, EPE | N/A |
| Completed | Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments. NCT04740827 | Allergan | Phase 3 |
| Completed | A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Epis NCT04686136 | AbbVie | Phase 3 |
| Recruiting | CGRP Inhibition, Autonomic Function, and Migraine NCT04628429 | Medical University of Vienna | — |
| Completed | A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Epis NCT04437433 | AbbVie | Phase 3 |
| Completed | Evaluation of Peripheral Nerve Stimulation for Acute Treatment of Migraine Pain NCT04166045 | Theranova, L.L.C. | N/A |
| Unknown | HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs NCT06155123 | IRCCS National Neurological Institute "C. Mondino" Foundation | — |
| Completed | A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine NCT03963232 | Eli Lilly and Company | Phase 3 |
| Completed | Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients NCT03927144 | Amgen | Phase 4 |
| Completed | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migr NCT03939312 | Allergan | Phase 3 |
| Completed | Occipital Blocks for Acute Migraine NCT03526874 | Children's Hospital of Philadelphia | Phase 3 |
| Completed | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Ep NCT03777059 | Allergan | Phase 3 |
| Completed | Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Mi NCT03700320 | Allergan | Phase 3 |
| Active Not Recruiting | A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine NCT03432286 | Eli Lilly and Company | Phase 3 |
| Completed | Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients NCT03333109 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Energy for the Brain NCT03132233 | University Hospital, Basel, Switzerland | N/A |
| Completed | A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Othe NCT03096834 | Novartis Pharmaceuticals | Phase 3 |
| Completed | DFN-11 Injection in Episodic Migraine With or Without Aura NCT02569853 | Dr. Reddy's Laboratories Limited | Phase 3 |
| Completed | Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine NCT02176018 | Cady, Roger, M.D. | Phase 2 |
| Completed | The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis NCT04031781 | Ain Shams University | N/A |
| Completed | Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Att NCT01230411 | Thomas Jefferson University | Phase 4 |
| Withdrawn | Aspirin Resistance in Women With Migraine NCT01257893 | Swedish Medical Center | N/A |
| Completed | fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of D NCT00868556 | The Cleveland Clinic | — |
| Completed | The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache NCT00719134 | Beth Israel Deaconess Medical Center | Phase 4 |